PubMed · 2015 · 43 citations · 0 references
MedicineImmunologyPathologyClinical BiochemistryHepatologyImmunopathologyBiomarkers Of Liver InjuryCirrhosisHepatic Function TestingHepatic PathologyLiver DiseaseLiver Function TestsChemiluminescent BiosensorsCirrhosis Biochemistry MarkersLiver ImmunologyPlasma In Liver DiseaseProthrombin Activation
The aim of this study was to evaluate the changes in serum galectin-3 concentration during liver diseases. The results were compared with hyaluronic acid concentration in combination with prothrombin index as a HAPRI index. Serum samples were obtained from 20 healthy volunteers and 109 patients suffering from alcoholic cirrhosis (AC)--57, non-alcoholic cirrhosis (NAC)--30 and toxic hepatitis (HT)--22 patients. Cirrhotic patients were classified according to Child-Pugh scale. Galectin-3 concentration was measured by the chemiluminescent microparticle immunoassay and HAPRI index was calculated using a formula. There was a significant increase in the serum concentration of galectin-3 in patients with AC, NAC and HT, and significant differences between diseases were observed. The mean galectin-3 concentration in AC was significantly higher than that in HT. The serum galectin-3 level differs significantly according to severity of cirrhosis and was the highest in Child-Pugh class C. The sensitivity, specificity, accuracy, positive and negative predictive values and the area under the ROC curve for galectin-3 and HAPRI were high and similar to each other. In conclusion, galectin-3 is a good marker of fibrosis in cirrhosis and toxic hepatitis, which reflects the stage of liver damage, like the HAPRI index.